RCC
MCID: RNL114
MIFTS: 79

Renal Cell Carcinoma, Nonpapillary (RCC)

Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Renal Cell Carcinoma, Nonpapillary

MalaCards integrated aliases for Renal Cell Carcinoma, Nonpapillary:

Name: Renal Cell Carcinoma, Nonpapillary 57 29 6
Renal Cell Carcinoma 57 12 73 20 58 72 36 29 6 15 17 70
Adenocarcinoma of Kidney 57 12 20 72
Rcc 57 12 58 72
Renal Carcinoma, Chromophobe, Somatic 57 13 6
Hypernephroma 57 12 72
Hereditary Clear Cell Renal Cell Carcinoma 58 70
Renal Cell Carcinoma, Clear Cell, Somatic 57 6
Nonpapillary Renal Cell Carcinoma 12 15
Renal Cell Carcinoma, Somatic 57 6
Renal Cell Adenocarcinoma 20 17
Carcinoma, Renal Cell 44 39
Hereditary Clear Cell Renal Cell Adenocarcinoma 58
Conventional Renal Cell Carcinoma 70
Carcinoma, Renal Cell, Nonpapillary 39
Renal Cell Carcinoma Non-Papillary 72
Conventional Renal Cell Carcinoma 72
Common Renal Cell Carcinoma 72
Clear Cell Renal Carcinoma 72
Carcinoma Renal Cell 54
Renal Cell Cancer 15
Ccrcc 72
Crcc 72

Characteristics:

Orphanet epidemiological data:

58
renal cell carcinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

HPO:

31
renal cell carcinoma, nonpapillary:
Inheritance sporadic


Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 12 DOID:0050387 DOID:4450
OMIM® 57 144700
KEGG 36 H00021
MeSH 44 D002292
NCIt 50 C9385
SNOMED-CT 67 254915003
MESH via Orphanet 45 D002292
ICD10 via Orphanet 33 C64
UMLS via Orphanet 71 C0007134
SNOMED-CT via HPO 68 41607009 702391001
UMLS 70 C0007134 C0279702 C1333985

Summaries for Renal Cell Carcinoma, Nonpapillary

OMIM® : 57 The Heidelberg histologic classification of renal cell tumors subdivides renal cell tumors into benign and malignant parenchymal neoplasms and, where possible, limits each subcategory to the most common documented genetic abnormalities (Kovacs et al., 1997). Malignant tumors are subclassified into common or conventional renal cell carcinoma (clear cell); papillary renal cell carcinoma; chromophobe renal cell carcinoma; collecting duct carcinoma, with medullary carcinoma of the kidney; and unclassified renal cell carcinoma. The common or conventional type accounts for about 75% of renal cell neoplasms and is characterized genetically by a highly specific deletion of chromosome 3p. Papillary renal cell carcinoma (see 605074) accounts for about 10% of renal cell tumors. Chromophobe renal cell carcinoma accounts for approximately 5% of renal cell neoplasms. Genetically, chromophobe RCC is characterized by a combination of loss of heterozygosity of chromosomes 1, 2, 6, 10, 13, 17, and 21 and hypodiploid DNA content. Collecting duct carcinoma accounts for about 1% of renal cell carcinoma. Renal cell carcinoma occurs nearly twice as often in men as in women; incidence in the United States is equivalent among whites and blacks. Cigarette smoking doubles the likelihood of renal cell carcinoma and contributes to as many as one-third of cases. Obesity is also a risk factor, particularly in women. Other risk factors include hypertension, unopposed estrogen therapy, and occupational exposure to petroleum products, heavy metals, or asbestos (summary by Motzer et al., 1996). (144700) (Updated 05-Apr-2021)

MalaCards based summary : Renal Cell Carcinoma, Nonpapillary, also known as renal cell carcinoma, is related to chromophobe renal cell carcinoma and kidney cancer, and has symptoms including flank pain An important gene associated with Renal Cell Carcinoma, Nonpapillary is FLCN (Folliculin), and among its related pathways/superpathways are Renal cell carcinoma and Transcriptional misregulation in cancer. The drugs Fentanyl and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and bone, and related phenotypes are renal cell carcinoma and immune system

Disease Ontology : 12 A renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the kidney.

KEGG : 36 Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.

UniProtKB/Swiss-Prot : 72 Renal cell carcinoma: Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non- papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype.

Wikipedia : 73 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Renal Cell Carcinoma, Nonpapillary

Diseases related to Renal Cell Carcinoma, Nonpapillary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1236)
# Related Disease Score Top Affiliating Genes
1 chromophobe renal cell carcinoma 33.6 VHL SETD2 RNF139 PBRM1 OGG1 HNF1B
2 kidney cancer 33.5 VHL SETD2 PBRM1 MTOR MIR200C MIR141
3 hereditary renal cell carcinoma 33.5 RNF139 MET FLCN FHIT
4 clear cell renal cell carcinoma 33.5 VHL TUG1 SETD2 RNF139 PBRM1 OGG1
5 clear cell papillary renal cell carcinoma 33.0 VHL PBRM1 HNF1A
6 renal cell carcinoma, papillary, 1 33.0 VHL SETD2 PBRM1 MTOR MET LOC107303340
7 von hippel-lindau syndrome 32.6 VHL MET LOC107303340
8 lung cancer susceptibility 3 31.9 TUG1 SETD2 OGG1 MIR200C MET FHIT
9 cholangiocarcinoma 31.5 TUG1 OGG1 MTOR MIR141 MET FHIT
10 kidney angiomyolipoma 31.5 MTOR FLCN
11 collecting duct carcinoma 31.3 VHL SETD2 PBRM1 FLCN FHIT
12 chordoma 31.2 PBRM1 MTOR MET
13 familial renal papillary carcinoma 31.1 MET FLCN
14 angiomatosis 31.0 VHL LOC107303340
15 ovarian clear cell adenocarcinoma 31.0 MTOR MET HNF1B
16 high grade glioma 30.9 TUG1 MTOR MET LINC00963 ATM
17 endolymphatic sac tumor 30.9 VHL LOC107303340
18 hepatoblastoma 30.8 TUG1 MTOR MET HNF1A
19 pheochromocytoma-paraganglioma 30.7 VHL LOC107303340
20 differentiated thyroid carcinoma 30.7 MET FHIT DIRC3
21 retinal hemangioblastoma 30.5 VHL LOC107303340
22 bladder urothelial carcinoma 30.4 TUG1 MTOR FHIT
23 melanoma, cutaneous malignant 8 11.4
24 multilocular cystic renal neoplasm of low malignant potential 11.4
25 childhood kidney cell carcinoma 11.4
26 eosinophilic variant of chromophobe renal cell carcinoma 11.3
27 mucinous tubular and spindle renal cell carcinoma 11.3
28 multilocular clear cell renal cell carcinoma 11.3
29 hereditary conventional renal cell carcinoma 11.3
30 bap1 tumor predisposition syndrome 11.2
31 birt-hogg-dube syndrome 11.2
32 classic variant of chromophobe renal cell carcinoma 11.1
33 cowden syndrome 1 11.1
34 cowden syndrome 4 11.0
35 cowden syndrome 5 11.0
36 cowden syndrome 6 11.0
37 cowden syndrome 7 11.0
38 chromophil renal cell carcinoma 11.0
39 thyroid carcinoma, papillary, with papillary renal neoplasia 10.9
40 renal cell carcinoma, xp11-associated 10.9
41 exanthem 10.8
42 hypothyroidism 10.8
43 chronic kidney disease 10.7
44 pulmonary embolism 10.7
45 chromosomal triplication 10.6
46 47,xyy 10.6
47 polycystic kidney disease 10.6
48 severe combined immunodeficiency 10.6
49 congenital myasthenic syndrome with episodic apnea 10.6 VHL LOC107303340
50 neuroblastoma 10.6

Graphical network of the top 20 diseases related to Renal Cell Carcinoma, Nonpapillary:



Diseases related to Renal Cell Carcinoma, Nonpapillary

Symptoms & Phenotypes for Renal Cell Carcinoma, Nonpapillary

Human phenotypes related to Renal Cell Carcinoma, Nonpapillary:

31
# Description HPO Frequency HPO Source Accession
1 renal cell carcinoma 31 HP:0005584

Clinical features from OMIM®:

144700 (Updated 05-Apr-2021)

UMLS symptoms related to Renal Cell Carcinoma, Nonpapillary:


flank pain

MGI Mouse Phenotypes related to Renal Cell Carcinoma, Nonpapillary:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.9 ATM FHIT FLCN HNF1B MET MTOR
2 liver/biliary system MP:0005370 9.5 HNF1A HNF1B MET OGG1 PBRM1 RNF139
3 neoplasm MP:0002006 9.17 ATM FHIT FLCN MET OGG1 SETD2

Drugs & Therapeutics for Renal Cell Carcinoma, Nonpapillary

Drugs for Renal Cell Carcinoma, Nonpapillary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 432)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
2
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
3
Nicotine Approved Phase 4 54-11-5 942 89594
4
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Caffeine Approved Phase 4 58-08-2 2519
7
Zoledronic Acid Approved Phase 4 118072-93-8 68740
8
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
9
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
10
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
11
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
12
Ipilimumab Approved Phase 4 477202-00-9
13 Neurotransmitter Agents Phase 4
14 Psychotropic Drugs Phase 4
15 Anesthetics Phase 4
16 Anesthetics, General Phase 4
17 Platelet Aggregation Inhibitors Phase 4
18 Adrenergic alpha-Agonists Phase 4
19 Adrenergic Agonists Phase 4
20 Adrenergic Agents Phase 4
21 Central Nervous System Stimulants Phase 4
22 Cholinergic Agents Phase 4
23 Nicotinic Agonists Phase 4
24 Antidepressive Agents Phase 4
25 Cytochrome P-450 Enzyme Inhibitors Phase 4
26 Dopamine Uptake Inhibitors Phase 4
27 Hypnotics and Sedatives Phase 4
28 GABA Modulators Phase 4
29 Anesthetics, Intravenous Phase 4
30 Phosphodiesterase Inhibitors Phase 4
31 Anesthetics, Local Phase 4
32 Analgesics, Opioid Phase 4
33 Vasoconstrictor Agents Phase 4
34 Adrenergic beta-Agonists Phase 4
35 Anti-Asthmatic Agents Phase 4
36 Respiratory System Agents Phase 4
37 Sympathomimetics Phase 4
38 Mydriatics Phase 4
39 Bronchodilator Agents Phase 4
40 Anesthetics, Inhalation Phase 4
41
tannic acid Approved Phase 2, Phase 3 1401-55-4
42
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
43
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
44
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
45
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
46
Etoposide Approved Phase 3 33419-42-0 36462
47
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
48
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
49
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
50
Promethazine Approved, Investigational Phase 3 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 1463)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
3 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
5 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Completed NCT02555748 Phase 4 Pazopanib;Sunitinib
6 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
7 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
8 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
9 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
10 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
11 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
12 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
13 Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Completed NCT00172003 Phase 4 Zoledronic acid
14 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
15 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
16 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
17 ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
18 Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings Recruiting NCT03821376 Phase 4 Contrast enhanced ultrasound with Lumason
19 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
20 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
21 A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India Not yet recruiting NCT04513522 Phase 4
22 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
23 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
24 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
25 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02570789 Phase 4 patients with sunitinib or pazopanib
26 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy Unknown status NCT01865747 Phase 3 Cabozantinib tablets;Everolimus (Afinitor) tablets
27 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
28 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
29 Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib Unknown status NCT00930033 Phase 3
30 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
31 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
32 A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma. Completed NCT01064310 Phase 3 pazopanib;sunitinib
33 An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192 Completed NCT00387764 Phase 3 pazopanib
34 A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy Completed NCT01235962 Phase 3 pazopanib;placebo;pazopanib;placebo
35 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Bevacizumab;Interferon-Alfa 9MU
36 Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma Completed NCT02030717 Phase 2, Phase 3 klonidin;epidural anesthesia
37 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma Completed NCT00738530 Phase 3 Bevacizumab [Avastin];Interferon alfa 2a [Roferon];Placebo
38 Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making. Completed NCT02883153 Phase 2, Phase 3 Zirconium-89 girentuximab PET/CT
39 Randomised,Double-blind,Placebo-controlled,Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma. Completed NCT00397345 Phase 3
40 An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients With Advanced Renal Cell Carcinoma Completed NCT00478114 Phase 3 sorafenib
41 A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma Completed NCT00334282 Phase 3 Pazopanib;placebo
42 A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma. Completed NCT00065468 Phase 3 Interferon Alfa;CCI-779;Interferon Alfa and CCI-779
43 An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma Completed NCT00492986 Phase 3 Nexavar (Sorafenib, BAY43-9006)
44 Open Label, Non-Comparative Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma Completed NCT00111020 Phase 3 Sorafenib (Nexavar, BAY43-9006)
45 A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma Completed NCT00083889 Phase 3 Interferon-alfa;SU011248
46 A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma Completed NCT00586105 Phase 3 Sorafenib (Nexavar, BAY43-9006)
47 A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer. Completed NCT00073307 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
48 Adjuvant Low-dose Interleukin-2 (IL2) Plus Interferone-alpha (IFN) in Operable Renal Cell Cancer (RCC). Phase III, Randomized, Multicenter Trial of the Italian Oncology Group for Clinical Research (GOIRC). Completed NCT00502034 Phase 3 Interferon Alfa-2a;Interleukin-2
49 A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma Completed NCT00033904 Phase 3 autologous human tumor-derived HSPPC-96
50 A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1) Completed NCT01030783 Phase 3 tivozanib (AV-951);Sorafenib

Search NIH Clinical Center for Renal Cell Carcinoma, Nonpapillary

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide

Cochrane evidence based reviews: carcinoma, renal cell

Genetic Tests for Renal Cell Carcinoma, Nonpapillary

Genetic tests related to Renal Cell Carcinoma, Nonpapillary:

# Genetic test Affiliating Genes
1 Renal Cell Carcinoma, Nonpapillary 29 FLCN HNF1A HNF1B OGG1 RNF139 VHL
2 Renal Cell Carcinoma 29

Anatomical Context for Renal Cell Carcinoma, Nonpapillary

MalaCards organs/tissues related to Renal Cell Carcinoma, Nonpapillary:

40
Kidney, Endothelial, Bone, Brain, Thyroid, Lung, Lymph Node

Publications for Renal Cell Carcinoma, Nonpapillary

Articles related to Renal Cell Carcinoma, Nonpapillary:

(show top 50) (show all 30802)
# Title Authors PMID Year
1
A germline mutation in PBRM1 predisposes to renal cell carcinoma. 57 6 61
25911086 2015
2
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. 54 6 57
15649945 2005
3
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. 54 6 61
10433944 1999
4
Integrated molecular analysis of clear-cell renal cell carcinoma. 61 57
23797736 2013
5
Comprehensive molecular characterization of clear cell renal cell carcinoma. 61 57
23792563 2013
6
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. 6 61
23213094 2013
7
BAP1 loss defines a new class of renal cell carcinoma. 57 61
22683710 2012
8
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 57 61
20054297 2010
9
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 47 61 54
18925646 2008
10
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. 57 61
18260086 2008
11
A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma. 57 61
17539022 2007
12
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. 57 61
17311301 2007
13
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. 61 57
16798883 2006
14
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. 57 61
16814207 2006
15
Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. 6 54
15371818 2004
16
Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. 57 61
15016767 2004
17
Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. 54 57
12837690 2003
18
The allelic loss of chromosome 3p25 with c-myc gain is related to the development of clear-cell renal cell carcinoma. 57 61
12694227 2003
19
Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. 61 6
11921283 2002
20
Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). 57 54
11284032 2001
21
Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. 61 57
10807693 2000
22
The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. 57 61
10232606 1999
23
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. 54 6
10327054 1999
24
Physical and functional mapping of a tumor suppressor locus for renal cell carcinoma within chromosome 3p12. 61 57
9721855 1998
25
The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. 61 57
9689122 1998
26
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. 6 54
9563489 1998
27
A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. 61 57
9461085 1998
28
The Heidelberg classification of renal cell tumours. 57 61
9390023 1997
29
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. 6 54
9140397 1997
30
Renal-cell carcinoma. 57 61
8778606 1996
31
Inhibition of transcription elongation by the VHL tumor suppressor protein. 54 6
7660122 1995
32
A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. 61 57
8159756 1994
33
Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. 61 57
1433648 1992
34
Allelic losses at chromosome 17p in human renal cell carcinoma are inversely related to allelic losses at chromosome 3p. 61 57
1348014 1992
35
Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. 61 57
1553556 1992
36
Molecular and cellular characterization of human renal cell carcinoma cell lines. 61 57
1345811 1992
37
The region of common allelic losses in sporadic renal cell carcinoma is bordered by the loci D3S2 and THRB. 61 57
1685475 1991
38
Allelic loss at chromosome 3p characterizes clear cell phenotype of renal cell carcinoma. 61 57
1671000 1991
39
Familial renal cell carcinoma: hereditary or coincidental? 61 57
2398557 1990
40
Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. 57 61
1969617 1990
41
A 1.5-megabase restriction map surrounding MYC does not include the translocation breakpoint in familial renal cell carcinoma. 57 61
2914707 1989
42
Recurrent genomic rearrangements are not at the fragile sites on chromosomes 3 and 5 in human renal cell carcinomas. 57 61
3417313 1988
43
Genomic defects in nonfamilial renal cell carcinoma. Possible specific chromosome change. 61 57
3395987 1988
44
Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma. 57 61
2835149 1988
45
Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. 61 57
2894030 1988
46
Specific chromosome aberration in human renal cell carcinoma. 61 57
3610386 1987
47
Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease. 61 57
3594418 1987
48
Deletion 3p: the only chromosome loss in a primary renal cell carcinoma. 57 61
3567881 1987
49
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. 57 61
2885753 1987
50
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus. 61 57
3467112 1986

Variations for Renal Cell Carcinoma, Nonpapillary

ClinVar genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

6 (show top 50) (show all 1341)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CTNNB1 NM_001904.4(CTNNB1):c.1374A>C (p.Glu458Asp) SNV other 438755 rs1553631848 GRCh37: 3:41275208-41275208
GRCh38: 3:41233717-41233717
2 OGG1 NM_002542.5(OGG1):c.137G>A (p.Arg46Gln) SNV Pathogenic 7602 rs104893751 GRCh37: 3:9792107-9792107
GRCh38: 3:9750423-9750423
3 PBRM1 NM_018313.5(PBRM1):c.3923_3930del (p.Asp1308fs) Deletion Pathogenic 218955 rs864321679 GRCh37: 3:52597380-52597387
GRCh38: 3:52563364-52563371
4 FLCN FLCN, 2-BP DEL, 1284TC AND 2-BP INS, 1284AC Indel Pathogenic 3368 GRCh37:
GRCh38:
5 HNF1B NM_000458.4(HNF1B):c.46del (p.Leu16fs) Deletion Pathogenic 12648 GRCh37: 17:36104830-36104830
GRCh38: 17:37744839-37744839
6 HNF1A NM_000545.6(HNF1A):c.814C>T (p.Arg272Cys) SNV Pathogenic 447503 rs1555212014 GRCh37: 12:121432067-121432067
GRCh38: 12:120994264-120994264
7 HNF1A NM_000545.6(HNF1A):c.1340C>T (p.Pro447Leu) SNV Pathogenic 14928 rs137853236 GRCh37: 12:121435307-121435307
GRCh38: 12:120997504-120997504
8 HNF1A NM_000545.6(HNF1A):c.92G>A (p.Gly31Asp) SNV Pathogenic 14948 rs137853247 GRCh37: 12:121416663-121416663
GRCh38: 12:120978860-120978860
9 HNF1A NM_000545.6(HNF1A):c.92G>A (p.Gly31Asp) SNV Pathogenic 14948 rs137853247 GRCh37: 12:121416663-121416663
GRCh38: 12:120978860-120978860
10 FLCN NM_144997.7(FLCN):c.1429C>T (p.Arg477Ter) SNV Pathogenic 253251 rs879255678 GRCh37: 17:17118502-17118502
GRCh38: 17:17215188-17215188
11 LOC107303340 , VHL NM_000551.3(VHL):c.548C>A (p.Ser183Ter) SNV Pathogenic 2215 rs5030823 GRCh37: 3:10191555-10191555
GRCh38: 3:10149871-10149871
12 ATM ATM, IVS61DS, 2-BP INS, +2TA Insertion Pathogenic 3037 GRCh37:
GRCh38:
13 MET NM_000245.4(MET):c.3392T>C (p.Met1131Thr) SNV Pathogenic 13881 rs121913668 GRCh37: 7:116418881-116418881
GRCh38: 7:116778827-116778827
14 MET NM_000245.4(MET):c.3562G>T (p.Val1188Leu) SNV Pathogenic 13882 rs121913669 GRCh37: 7:116422081-116422081
GRCh38: 7:116782027-116782027
15 MET NM_000245.4(MET):c.3682G>A (p.Asp1228Asn) SNV Pathogenic 13884 rs121913671 GRCh37: 7:116423407-116423407
GRCh38: 7:116783353-116783353
16 MET NM_000245.4(MET):c.3689A>G (p.Tyr1230Cys) SNV Pathogenic 13885 rs121913246 GRCh37: 7:116423414-116423414
GRCh38: 7:116783360-116783360
17 MET NM_000245.4(MET):c.3583C>G (p.Leu1195Val) SNV Pathogenic 13886 rs121913673 GRCh37: 7:116422102-116422102
GRCh38: 7:116782048-116782048
18 MET NM_000245.4(MET):c.3274G>A (p.Val1092Ile) SNV Pathogenic 186141 rs786202724 GRCh37: 7:116417457-116417457
GRCh38: 7:116777403-116777403
19 LOC107303340 , VHL NM_000551.3(VHL):c.499C>T (p.Arg167Trp) SNV Pathogenic 2218 rs5030820 GRCh37: 3:10191506-10191506
GRCh38: 3:10149822-10149822
20 LOC107303340 , VHL NM_001354723.2(VHL):c.*84_*90del Deletion Pathogenic 694389 rs1575932266 GRCh37: 3:10191534-10191540
GRCh38: 3:10149850-10149856
21 MTOR NM_004958.4(MTOR):c.3026G>A (p.Arg1009Gln) SNV Pathogenic 801436 rs778855567 GRCh37: 1:11288729-11288729
GRCh38: 1:11228672-11228672
22 MET NM_000245.4(MET):c.3281A>G (p.His1094Arg) SNV Pathogenic 13887 rs121913243 GRCh37: 7:116417464-116417464
GRCh38: 7:116777410-116777410
23 HNF1A NM_000545.6(HNF1A):c.872dup (p.Gly292fs) Duplication Pathogenic 14927 rs587776825 GRCh37: 12:121432117-121432118
GRCh38: 12:120994314-120994315
24 HNF1A NM_000545.6(HNF1A):c.1135C>G (p.Pro379Ala) SNV Pathogenic 431970 rs754729248 GRCh37: 12:121434371-121434371
GRCh38: 12:120996568-120996568
25 TP53 NM_000546.5(TP53):c.641A>G (p.His214Arg) SNV Likely pathogenic 376615 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
26 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 GRCh37: 1:115256529-115256529
GRCh38: 1:114713908-114713908
27 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala) SNV Likely pathogenic 13659 rs121913274 GRCh37: 3:178936092-178936092
GRCh38: 3:179218304-179218304
28 TP53 NM_000546.6(TP53):c.659A>G (p.Tyr220Cys) SNV Likely pathogenic 127819 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
29 TP53 NM_000546.5(TP53):c.526T>A (p.Cys176Ser) SNV Likely pathogenic 376570 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
30 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln) SNV Likely pathogenic 7829 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
31 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
32 TP53 NM_000546.5(TP53):c.715A>G (p.Asn239Asp) SNV Likely pathogenic 234036 rs876660807 GRCh37: 17:7577566-7577566
GRCh38: 17:7674248-7674248
33 TP53 NM_000546.5(TP53):c.373A>C (p.Thr125Pro) SNV Likely pathogenic 376666 rs1057520003 GRCh37: 17:7579314-7579314
GRCh38: 17:7675996-7675996
34 PIK3CA NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys) SNV Likely pathogenic 13655 rs104886003 GRCh37: 3:178936091-178936091
GRCh38: 3:179218303-179218303
35 PIK3CA NM_006218.4(PIK3CA):c.241G>A (p.Glu81Lys) SNV Likely pathogenic 376478 rs1057519929 GRCh37: 3:178916854-178916854
GRCh38: 3:179199066-179199066
36 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Likely pathogenic 13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
37 TP53 NM_000546.5(TP53):c.526T>C (p.Cys176Arg) SNV Likely pathogenic 376573 rs967461896 GRCh37: 17:7578404-7578404
GRCh38: 17:7675086-7675086
38 TP53 NM_000546.5(TP53):c.815T>A (p.Val272Glu) SNV Likely pathogenic 376673 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
39 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala) SNV Likely pathogenic 376665 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
40 MET NM_000245.4(MET):c.3658G>A (p.Val1220Ile) SNV Likely pathogenic 13883 rs121913670 GRCh37: 7:116423383-116423383
GRCh38: 7:116783329-116783329
41 FLCN NM_144997.7(FLCN):c.779+1G>T SNV Likely pathogenic 231274 rs758175953 GRCh37: 17:17125814-17125814
GRCh38: 17:17222500-17222500
42 VHL NM_000551.4(VHL):c.319C>G (p.Arg107Gly) SNV Likely pathogenic 43599 rs397516440 GRCh37: 3:10183850-10183850
GRCh38: 3:10142166-10142166
43 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser) SNV Likely pathogenic 12383 rs121912666 GRCh37: 17:7578190-7578190
GRCh38: 17:7674872-7674872
44 PTEN NM_001304718.2(PTEN):c.-363C>G SNV Likely pathogenic 375958 rs121909224 GRCh37: 10:89692904-89692904
GRCh38: 10:87933147-87933147
45 VHL NM_000551.3(VHL):c.266T>A (p.Leu89His) SNV Likely pathogenic 376047 rs5030807 GRCh37: 3:10183797-10183797
GRCh38: 3:10142113-10142113
46 TP53 NM_000546.6(TP53):c.422G>T SNV Likely pathogenic 376568 rs587781288 GRCh37: 17:7578508-7578508
GRCh38: 17:7675190-7675190
47 TP53 NM_000546.5(TP53):c.814G>A (p.Val272Met) SNV Likely pathogenic 185814 rs121912657 GRCh37: 17:7577124-7577124
GRCh38: 17:7673806-7673806
48 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro) SNV Likely pathogenic 376664 rs1057520002 GRCh37: 17:7577560-7577560
GRCh38: 17:7674242-7674242
49 TP53 NM_000546.5(TP53):c.613T>A (p.Tyr205Asn) SNV Likely pathogenic 376684 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
50 TP53 NM_000546.5(TP53):c.614A>T (p.Tyr205Phe) SNV Likely pathogenic 376682 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917

UniProtKB/Swiss-Prot genetic disease variations for Renal Cell Carcinoma, Nonpapillary:

72
# Symbol AA change Variation ID SNP ID
1 FLCN p.Arg239Cys VAR_066026 rs78683075
2 SETD2 p.Asn1733Asp VAR_069812
3 SETD2 p.Ser1769Pro VAR_069813
4 VHL p.Leu163Pro VAR_034998 rs28940297

Cosmic variations for Renal Cell Carcinoma, Nonpapillary:

9 (show top 50) (show all 7561)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143616890 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2108A>C p.Q703P 2:184937759-184937759 15
2 COSM88579140 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.2363A>C p.Q788P 2:184937759-184937759 15
3 COSM88566796 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.121G>C p.E41Q 2:184866378-184866378 15
4 COSM143612455 ZNF804A kidney,NS,carcinoma,clear cell renal cell carcinoma c.-135G>C p.? 2:184866378-184866378 15
5 COSM100952565 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 15
6 COSM100946000 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 15
7 COSM85796182 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 15
8 COSM144685741 ZNF800 kidney,NS,carcinoma,clear cell renal cell carcinoma c.719A>G p.N240S 7:127374617-127374617 15
9 COSM131496685 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 15
10 COSM94790253 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3298A>G p.S1100G 18:25224620-25224620 15
11 COSM140713700 ZNF521 kidney,NS,carcinoma,clear cell renal cell carcinoma c.2638A>G p.S880G 18:25224620-25224620 15
12 COSM87583829 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.7085G>A p.R2362Q 9:107003322-107003322 15
13 COSM109100722 ZNF462 kidney,NS,carcinoma,papillary renal cell carcinoma c.3803G>A p.R1268Q 9:107003322-107003322 15
14 COSM84285389 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 15
15 COSM132161238 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3208G>A p.V1070I 16:49626188-49626188 15
16 COSM136721462 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3379G>A p.V1127I 16:49626188-49626188 15
17 COSM136000826 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3379G>A p.V1127I 16:49626188-49626188 15
18 COSM137730910 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3208G>A p.V1070I 16:49626188-49626188 15
19 COSM137390699 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3559G>A p.V1187I 16:49626188-49626188 15
20 COSM137183617 ZNF423 kidney,NS,carcinoma,clear cell renal cell carcinoma c.3379G>A p.V1127I 16:49626188-49626188 15
21 COSM151995781 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 1:200407613-200407613 15
22 COSM93625940 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.2093C>T p.P698L 1:200407613-200407613 15
23 COSM93623781 ZNF281 kidney,NS,carcinoma,papillary renal cell carcinoma c.1985C>T p.P662L 1:200407613-200407613 15
24 COSM140954956 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 19:44131801-44131801 15
25 COSM140688909 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.*968G>T p.? 19:44131801-44131801 15
26 COSM85326448 ZNF225 kidney,NS,carcinoma,papillary renal cell carcinoma c.1187G>T p.G396V 19:44131801-44131801 15
27 COSM112895347 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3811G>T p.D1271Y 2:218642705-218642705 15
28 COSM105902090 ZNF142 kidney,NS,carcinoma,papillary renal cell carcinoma c.3811G>T p.D1271Y 2:218642705-218642705 15
29 COSM102023492 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.-23-6591T>C p.? 16:72957556-72957556 15
30 COSM87285263 ZFHX3 kidney,NS,carcinoma,chromophobe renal cell carcinoma c.4509G>T p.Q1503H 16:72798173-72798173 15
31 COSM149301355 ZFHX3 kidney,NS,carcinoma,chromophobe renal cell carcinoma c.4509G>T p.Q1503H 16:72798173-72798173 15
32 COSM149268221 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 15
33 COSM102035738 ZFHX3 kidney,NS,carcinoma,chromophobe renal cell carcinoma c.1767G>T p.Q589H 16:72798173-72798173 15
34 COSM87274574 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.2590T>C p.Y864H 16:72957556-72957556 15
35 COSM102022298 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.4310G>A p.C1437Y 16:72795630-72795630 15
36 COSM102022947 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.-23-8436G>A p.? 16:72959401-72959401 15
37 COSM149269629 ZFHX3 kidney,NS,carcinoma,papillary renal cell carcinoma c.2590T>C p.Y864H 16:72957556-72957556 15
38 COSM87274133 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.745G>A p.G249S 16:72959401-72959401 15
39 COSM87273419 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 15
40 COSM149266502 ZFHX3 kidney,NS,carcinoma,clear cell renal cell carcinoma c.7052G>A p.C2351Y 16:72795630-72795630 15
41 COSM89411866 ZBTB2 kidney,NS,carcinoma,papillary renal cell carcinoma c.931G>A p.E311K 6:151366135-151366135 15
42 COSM152022098 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 15
43 COSM89895108 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1069T>A p.L357I 18:739803-739803 15
44 COSM136836927 YES1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.1084T>A p.L362I 18:739803-739803 15
45 COSM133267864 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
46 COSM143036610 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
47 COSM145023517 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
48 COSM127993611 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
49 COSM90943050 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.374C>G p.A125G 11:102114196-102114196 15
50 COSM126968507 YAP1 kidney,NS,carcinoma,clear cell renal cell carcinoma c.-161C>G p.? 11:102114196-102114196 15

Copy number variations for Renal Cell Carcinoma, Nonpapillary from CNVD:

7 (show top 50) (show all 1298)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14830 1 1104523 1105523 Gain Renal cell carcinoma
2 16766 1 13658511 13659511 Gain Renal cell carcinoma
3 16770 1 13703176 13704176 Loss Renal cell carcinoma
4 16773 1 13722829 13723829 Gain Renal cell carcinoma
5 19216 1 14925199 15393109 Loss Renal cell carcinoma
6 24428 1 180300000 185800000 Copy number Renal cell carcinoma
7 26325 1 199103044 199104044 Gain Renal cell carcinoma
8 27335 1 207179162 207180162 Gain Renal cell carcinoma
9 27861 1 214500000 224100000 Gain Renal cell carcinoma
10 30088 1 24000000 26000000 Loss Renal cell carcinoma
11 31042 1 24862824 24867531 Loss RCAN3 Renal cell carcinoma
12 31527 1 28000000 30200000 Loss Renal cell carcinoma
13 33893 1 5000000 7000000 Loss Renal cell carcinoma
14 42189 10 3000000 17300000 Copy number Renal cell carcinoma
15 42932 10 42300000 52900000 Copy number Renal cell carcinoma
16 49432 11 106916419 134173875 Loss Renal cell carcinoma
17 49705 11 110400000 121200000 Copy number Renal cell carcinoma
18 51840 11 13182721 13183721 Gain Renal cell carcinoma
19 51843 11 13184856 13185856 Loss Renal cell carcinoma
20 52861 11 21000000 57000000 Gain Renal cell carcinoma
21 53056 11 23642584 23643584 Gain Renal cell carcinoma
22 53595 11 31000000 43500000 Copy number Renal cell carcinoma
23 53953 11 35317771 35318771 Gain Renal cell carcinoma
24 60490 11 87000000 107000000 Gain Renal cell carcinoma
25 64438 12 12800000 14800000 Copy number Renal cell carcinoma
26 67031 12 35000000 69000000 Gain Renal cell carcinoma
27 67043 12 35400000 132349534 Gain Renal cell carcinoma
28 69398 12 54900000 58100000 Copy number Renal cell carcinoma
29 72532 12 82000000 100000000 Gain Renal cell carcinoma
30 75379 13 19500000 23300000 Loss Renal cell carcinoma
31 75593 13 21548578 21635655 Copy number Renal cell carcinoma
32 82801 14 15600000 106368585 Copy number Renal cell carcinoma
33 82818 14 15600000 106368585 Loss Renal cell carcinoma
34 83187 14 19387587 106241517 Loss Renal cell carcinoma
35 85229 14 41000000 48000000 Gain Renal cell carcinoma
36 87551 14 74550219 74587988 Loss MLH3 Renal cell carcinoma
37 88249 14 88692268 89155247 Loss FOXN3 Renal cell carcinoma
38 88312 14 89800000 91900000 Copy number Renal cell carcinoma
39 89170 15 100153615 100154615 Gain Renal cell carcinoma
40 90158 15 20233523 20234523 Gain Renal cell carcinoma
41 90187 15 20359182 20360182 Gain Renal cell carcinoma
42 90188 15 20359229 20360229 Gain Renal cell carcinoma
43 90209 15 20439260 20440260 Loss Renal cell carcinoma
44 90210 15 20442152 20442452 Loss Renal cell carcinoma
45 90214 15 20449913 20450913 Gain Renal cell carcinoma
46 90215 15 20450115 20451115 Loss Renal cell carcinoma
47 90218 15 20535877 20536877 Loss Renal cell carcinoma
48 90224 15 20611271 20612271 Loss Renal cell carcinoma
49 90229 15 20643792 20644792 Loss Renal cell carcinoma
50 90232 15 20666179 20666479 Loss Renal cell carcinoma

Expression for Renal Cell Carcinoma, Nonpapillary

LifeMap Discovery
Genes differentially expressed in tissues of Renal Cell Carcinoma, Nonpapillary patients vs. healthy controls: 35 (show top 50) (show all 277)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SLC12A1 solute carrier family 12 member 1 Kidney - 9.35 0.000
2 CALB1 calbindin 1 Kidney - 8.95 0.000
3 FXYD4 FXYD domain containing ion transport regulator 4 Kidney - 8.29 0.000
4 CLDN8 claudin 8 Kidney - 8.20 0.000
5 KCNJ1 potassium inwardly rectifying channel subfamily J member 1 Kidney - 8.20 0.000
6 NPHS2 NPHS2 stomatin family member, podocin Kidney - 8.18 0.000
7 MUC15 mucin 15, cell surface associated Kidney - 7.96 0.000
8 SCNN1G sodium channel epithelial 1 subunit gamma Kidney - 7.91 0.000
9 HPD 4-hydroxyphenylpyruvate dioxygenase Kidney - 7.78 0.000
10 FABP1 fatty acid binding protein 1 Kidney - 7.74 0.000
11 DNASE1 deoxyribonuclease 1 Kidney - 7.59 0.000
12 SLC7A13 solute carrier family 7 member 13 Kidney - 7.29 0.000
13 ANGPTL4 angiopoietin like 4 Kidney + 7.25 0.000
14 TNFAIP6 TNF alpha induced protein 6 Kidney + 7.16 0.000
15 ATP6V0A4 ATPase H+ transporting V0 subunit a4 Kidney - 7.13 0.000
16 PCP4 Purkinje cell protein 4 Kidney - 7.13 0.000
17 KNG1 kininogen 1 Kidney - 7.12 0.000
18 TYRP1 tyrosinase related protein 1 Kidney - 7.10 0.000
19 FGF9 fibroblast growth factor 9 Kidney - 6.99 0.000
20 EGF epidermal growth factor Kidney - 6.92 0.000
21 RALYL RALY RNA binding protein like Kidney - 6.81 0.000
22 PVALB parvalbumin Kidney - 6.73 0.000
23 KCNJ10 potassium inwardly rectifying channel subfamily J member 10 Kidney - 6.69 0.000
24 TMEM213 transmembrane protein 213 Kidney - 6.64 0.000
25 SLC22A8 solute carrier family 22 member 8 Kidney - 6.58 0.000
26 IRX2 iroquois homeobox 2 Kidney - 6.56 0.000
27 SLC26A7 solute carrier family 26 member 7 Kidney - 6.56 0.000
28 SLC4A1 solute carrier family 4 member 1 (Diego blood group) Kidney - 6.53 0.000
29 GPC5 glypican 5 Kidney - 6.53 0.000
30 RHCG Rh family C glycoprotein Kidney - 6.52 0.000
31 SOST sclerostin Kidney - 6.51 0.000
32 SFRP1 secreted frizzled related protein 1 Kidney - 6.49 0.000
33 HEPACAM2 HEPACAM family member 2 Kidney - 6.45 0.000
34 NELL1 neural EGFL like 1 Kidney - 6.38 0.000
35 SERPINA5 serpin family A member 5 Kidney - 6.34 0.000
36 RAB25 RAB25, member RAS oncogene family Kidney - 6.32 0.000
37 TMPRSS2 transmembrane serine protease 2 Kidney - 6.31 0.000
38 TMEM52B transmembrane protein 52B Kidney - 6.28 0.000
39 ERBB4 erb-b2 receptor tyrosine kinase 4 Kidney - 6.26 0.000
40 SOSTDC1 sclerostin domain containing 1 Kidney - 6.25 0.000
41 SH3GL2 SH3 domain containing GRB2 like 2, endophilin A1 Kidney - 6.16 0.000
42 ALDOB aldolase, fructose-bisphosphate B Kidney - 6.13 0.003
43 APOC1 apolipoprotein C1 Kidney + 6.11 0.000
44 UMOD uromodulin Kidney - 6.07 0.000
45 NPTX2 neuronal pentraxin 2 Kidney + 6.05 0.000
46 MFSD4A-AS1 MFSD4A antisense RNA 1 Kidney - 6.02 0.000
47 ESRRB estrogen related receptor beta Kidney - 5.99 0.000
48 SLC13A3 solute carrier family 13 member 3 Kidney - 5.96 0.001
49 TSPAN8 tetraspanin 8 Kidney - 5.96 0.000
50 WNK4 WNK lysine deficient protein kinase 4 Kidney - 5.94 0.000
Search GEO for disease gene expression data for Renal Cell Carcinoma, Nonpapillary.

Pathways for Renal Cell Carcinoma, Nonpapillary

Pathways related to Renal Cell Carcinoma, Nonpapillary according to KEGG:

36
# Name Kegg Source Accession
1 Renal cell carcinoma hsa05211
2 Transcriptional misregulation in cancer hsa05202

Pathways related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.51 MTOR MIR200C MIR141 MET ATM
2
Show member pathways
11.11 MTOR HNF1B HNF1A

GO Terms for Renal Cell Carcinoma, Nonpapillary

Biological processes related to Renal Cell Carcinoma, Nonpapillary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 liver development GO:0001889 9.33 MET HNF1B HNF1A
2 TOR signaling GO:0031929 9.32 MTOR FLCN
3 positive regulation of transcription initiation from RNA polymerase II promoter GO:0060261 9.26 HNF1B HNF1A
4 pancreas development GO:0031016 9.13 MET HNF1B HNF1A
5 regulation of pronephros size GO:0035565 8.62 HNF1B HNF1A

Sources for Renal Cell Carcinoma, Nonpapillary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....